BETA
Beta Drugs Limited (BETA) Stock Analysis
Beta Drugs Limited is an Indian pharmaceutical company focused on formulations and healthcare products. It develops and markets medicines for therapeutic segments served through distributors and chemists. The company competes in the domestic generic and specialty pharma market. It is listed on Indian stock exchanges and operates from India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹2,077.30
-1.94% 1W | +12.10% 52W
Market Cap
2.1k CR
P/E Ratio
47
52W High
₹2807.9
52W Low
₹990.1
Div. Yield
0%
Beta
-0.5
50 DMA
₹2290.9
200 DMA
₹1670.1
Profit Margin
11.1%
Inst. Own.
0%
📉 CONSOLIDATING DOWN
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% |
| Other Income | -1 | 2 | 3 | 3 | 2 | 3 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 |
| Profit before tax | 12 | 12 | 16 | 16 | 10 | 12 | 22 |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 |
| EPS in Rs | 8.86 | 8.95 | 11.59 | 12.11 | 8.40 | 8.93 | 14.25 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 385 | 410 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 | 327 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 | 83 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 | 10 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 | 15 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 | 18 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 | 61 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | 24% | |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 | 46 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.60 | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 | 43.69 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 19.0% | 27.0% | – |
| Profit CAGR | 11.0% | 29.0% | – |
Shareholding Pattern
Promoters66.73%
FIIs0.90%
DIIs0.26%
Public32.11%
Promoters66.73%
FIIs0.90%
DIIs0.29%
Public32.07%
Promoters64.90%
FIIs1.14%
DIIs1.90%
Public32.07%
Promoters64.63%
FIIs1.16%
DIIs2.15%
Public32.06%
Promoters59.10%
FIIs1.02%
DIIs6.23%
Public33.65%
Promoters66.73%
FIIs0.29%
DIIs0.04%
Public32.94%
Promoters66.73%
FIIs0.32%
DIIs0.06%
Public32.87%
Promoters66.73%
FIIs0.90%
DIIs0.17%
Public32.20%
Promoters64.63%
FIIs1.16%
DIIs2.15%
Public32.06%
Promoters59.10%
FIIs1.02%
DIIs6.23%
Public33.65%
BETA
Holdings Analysis
Key strengths & risk signals
59
Overall
62
Fundamental
57
Technical
Risks (3)
OVERVALUED! PEG of 4.48 means expensive relative to growth rate.
RECOVERY MODE! Current price (2077.3) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.9% (1 week), 14.6% (1 month), 0.8% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (2290.9) is above 200-day average (1670.1) - positive signal.
LOW VOLATILITY! Beta of -0.50 - stable stock, less market risk.
POSITIVE YEAR! Stock gained 12.1% in the last year.
Fundamental & Technical Analysis
59Overall
62Fundamental
57Technical
Fundamental Breakdown
Growth Quality
24/30
Revenue CAGR: 19.2% (VERY GOOD, 13/15). Profit CAGR: 10.5% (GOOD, 11/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.1% profit margin - acceptable profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 4.48 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 32.93% public ownership - moderate retail influence.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2290.9) is above 200-day average (1670.1) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (2077.3) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
6/10
POSITIVE YEAR! Stock gained 12.1% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 31,774 vs down days: 32,035. Ratio: 0.99x
RSI
3/5
NEUTRAL! RSI at 42.1 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 59.8% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.9% (1 week), 14.6% (1 month), 0.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of -0.50 - stable stock, less market risk.
BETA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-22 | Concall PDF | |
| Q2FY262025-11-13 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BETA | ₹2,077.30 | 47 | 11.1% | 19.2% | 10.5% | +12.1% | 59 | CONSOLIDATING DOWN | +35.0% | +75.6% | +25.2% | +33.5% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| SYNCOMF | ₹19.90 | 22.1 | 17.2% | 29.4% | 56.2% | +14.3% | 83 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| HESTERBIO | ₹2,193.30 | 13.8 | 41.6% | 7.7% | 27.8% | +10.0% | 73 | CONSOLIDATING UP | +491.5% | +506.3% | -8.2% | -22.9% |
| WINDLAS | ₹1,129.40 | 36.2 | 7.1% | 20.7% | 16.0% | +17.5% | 84 | BREAKOUT | 0.0% | +10.6% | +18.1% | +4.0% |
| INDOCO | ₹257.50 | 357.6 | 0.3% | 3.0% | – | -16.6% | 63 | BREAKOUT | -281.6% | -400.9% | +8.2% | +2.3% |
| SAKAR | ₹1,160.00 | 84.1 | 13.3% | 22.0% | 23.0% | +240.5% | 80 | CONSOLIDATING DOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| JAGSNPHARM | ₹227.00 | 33.8 | 15.5% | 6.7% | 17.3% | -3.9% | 71 | CONSOLIDATING UP | +22.2% | +50.0% | +8.7% | +28.0% |
Data from TradeAlone · Updated daily
No news tagged for BETA yet.
